LeMaitre shares fell 5.0% after earnings, despite 12% organic sales growth. The likely concern is the cost of growth: operating expenses rose 18%, faster than sales, while full-year guidance calls for 11% organic growth—below Q3’s pace.
LeMaitre Vascular’s shares fell 3.7% post-earnings, reflecting investor disappointment despite solid sales and EPS growth, driven primarily by cautious gross margin guidance and deceleration in unit growth within the distribution business.